American researchers report that alpha cells in the pancreas can produce GLP-1 themselves, pointing to a second source of the hormone beyond the gut.
Recap by typeshit. Post by Facebook on Facebook.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
An investor take on Indian contract manufacturers: the argument is that spending on plants for peptides, ADCs and oligos matters more than concall buzz.
EMY says a newer group of obesity drugs is beating Ozempic, though the drugs and data behind the claim aren't named here.
Loading…